Filtered By:
Management: Funding
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 373 results found since Jan 2013.
Researchers Find Alternative Pathways to HIV Antibodies
Contact: Sarah Avery Phone: 919-660-1306 Email: sarah.avery@duke.edu https://www.dukehealth.org
FOR IMMEDIATE RELEASE on Tuesday, May 3, 2016
DURHAM, N.C. – The immune system appears to hamper an investigational vaccine from inducing antibodies that protect against HIV infection, but there may be ways to overcome this impediment, according to research led by the Duke Human Vaccine Institute.
Using mouse and monkey models, the researchers showed they could could identify the roadblocks to inducing the broadly neutralizing antibodies that are considered imperative for successful protection against infection.
They then fo...
Source: DukeHealth.org: Duke Health Features - May 3, 2016 Category: Pediatrics Tags: Duke Medicine Source Type: news
Correction
With regard to the article in the January 2016 issue entitled “Sirtuin 1 attenuates nasal polypogenesis by suppressing epithelial-to-mesenchymal transition” (J Allergy Clin Immunol 2016;137:87-98), the authors report an incorrect funding statement, which should read as follows:
Source: Journal of Allergy and Clinical Immunology - April 30, 2016 Category: Allergy & Immunology Tags: Correction Source Type: research
Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda
Publication date: May 2016 Source:The Lancet HIV, Volume 3, Issue 5 Author(s): Ruanne V Barnabas, Heidi van Rooyen, Elioda Tumwesigye, Justin Brantley, Jared M Baeten, Alastair van Heerden, Bosco Turyamureeba, Philip Joseph, Meighan Krows, Katherine K Thomas, Torin T Schaafsma, James P Hughes, Connie Celum Background Male circumcision decreases HIV acquisition by 60%, and antiretroviral therapy (ART) almost eliminates HIV transmission from HIV-positive people who are virally suppressed; however, coverage of these interventions has lagged behind targets. We aimed to assess whether community-based HIV testing ...
Source: The Lancet HIV - April 30, 2016 Category: Infectious Diseases Source Type: research
Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study
We examined loss to follow-up and retention in care in patients in the option B+ programme during their first 3 years on ART. Methods We analysed two data sources: aggregated facility-level data about patients in option B+ who started ART between Oct 1, 2011, and June 30, 2012, at 546 health facilities; and patient-level data from 20 large facilities with electronic medical record system for HIV-positive women who started ART between Sept 1, 2011, and Dec 31, 2013, under option B+ or because they had WHO clinical stages 3 or 4 disease or had CD4 counts of less than 350 cells per μL. We used facility-level data to calcula...
Source: The Lancet HIV - April 30, 2016 Category: Infectious Diseases Source Type: research
Zika Emergency Funding Remains Stalled in Congress
Funding to fight the ongoing Zika virus outbreak remains tied up in bureaucracy as the U.S. Senate adjourned for a week-long recess after hearing arguments over the best way to fund the fight against the virus.
“We shouldn’t be taking 10 days off as a dangerous virus threatens this nation,” Senate Minority Leader Harry Reid said, the Atlantic reports. “And it is threatening us.”
The White House asked Congress for $1.9 billion in Zika emergency funding in February. Some funds that were allocated to the Ebola response have been repurposed to help with Zika, but health officials argue more is nee...
Source: TIME: Top Science and Health Stories - April 29, 2016 Category: Science Authors: Alexandra Sifferlin Tags: Uncategorized Funding recess Senate Zika Source Type: news
U.S. Officials Warn Zika 'Scarier' Than Initially Thought
By Timothy Gardner and Jeff Mason WASHINGTON (Reuters) - Top health officials expressed heightened concern on Monday about the threat posed to the United States by the Zika virus, saying the mosquito that spreads it is now present in about 30 states and hundreds of thousands of infections could appear in Puerto Rico. At a White House briefing, they stepped up pressure on the Republican-led Congress to pass approximately $1.9 billion in emergency funding for Zika preparedness that the Obama administration requested in February. "Everything we look at with this virus seems to be a bit scarier than we initially thought," said...
Source: Healthy Living - The Huffington Post - April 12, 2016 Category: Consumer Health News Source Type: news
Windgap Medical raises $3m for epinephrine auto-injector
Windgap Medical said in a regulatory filing today that it raised a debt-and-options round worth $2.9 million for the epinephrine auto-injector it’s developing.
Somerville, Mass.-based Windgap is working on a device that would mix a dry formulation of the drug into solution, then inject it into a patient suffering from anaphylaxis due to an acute allergy attack.
The device is designed to be smaller than the market leading EpiPen made by Mylan (NSDQ:MYL) and eliminate the shelf life problems associate with liquid epinephrine.
The funding round involved 46 unnamed investors, according to the filing.
The post Windgap Med...
Source: Mass Device - April 8, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Drug-Device Combinations Funding Roundup Windgap Medical Source Type: news
Correction
With regard to the article in the June 2014 issue entitled “Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency” (J Allergy Clin Immunol 2014;133:1660-6), the authors report an incorrect funding statement, which should read as follows: W.Q. and H.G. are supported by GOSHCC trustees. This research was supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London.
Source: Journal of Allergy and Clinical Immunology - March 31, 2016 Category: Allergy & Immunology Tags: Correction Source Type: research
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial
Publication date: 19–25 March 2016 Source:The Lancet, Volume 387, Issue 10024 Author(s): Mina C Hosseinipour, Gregory P Bisson, Sachiko Miyahara, Xin Sun, Agnes Moses, Cynthia Riviere, Fredrick K Kirui, Sharlaa Badal-Faesen, David Lagat, Mulinda Nyirenda, Kogieleum Naidoo, James Hakim, Peter Mugyenyi, German Henostroza, Paul D Leger, Javier R Lama, Lerato Mohapi, Jorge Alave, Vidya Mave, Valdilea G Veloso, Sandy Pillay, Nagalingeswaran Kumarasamy, Jing Bao, Evelyn Hogg, Lynne Jones, Andrew Zolopa, Johnstone Kumwenda, Amita Gupta Background Mortality within the first 6 months after initiating...
Source: The Lancet - March 18, 2016 Category: Journals (General) Source Type: research
Nonallergic Rhinitis
Nonallergic rhinitis (NAR) is one of the most common conditions in medicine, affecting the quality of life of millions of patients throughout the United States. Despite its ubiquitous nature, NAR remains a poorly managed and often difficult to treat condition. NAR is often suboptimally managed by clinicians with poor clinical outcomes. Establishing the correct diagnosis requires a keen understanding of the unique underlying mechanisms involved in NAR, which is still evolving. Ultimately epidemiologic studies that better define NAR prevalence and its economic burden on society are needed to convince funding agencies of the ...
Source: Immunology and Allergy Clinics of North America - March 12, 2016 Category: Allergy & Immunology Authors: Justin Greiwe, Jonathan A. Bernstein Source Type: research
Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis
Publication date: Available online 20 February 2016 Source:The Lancet Respiratory Medicine Author(s): Timothy E Sweeney, Lindsay Braviak, Cristina M Tato, Purvesh Khatri Background Active pulmonary tuberculosis is difficult to diagnose and treatment response is difficult to effectively monitor. A WHO consensus statement has called for new non-sputum diagnostics. The aim of this study was to use an integrated multicohort analysis of samples from publically available datasets to derive a diagnostic gene set in the peripheral blood of patients with active tuberculosis. Methods We searched two public gene expression mic...
Source: The Lancet Respiratory Medicine - February 20, 2016 Category: Respiratory Medicine Source Type: research
Hearing on Emerging Health Threats and the Zika Supplemental Funding Request
U.S. Senate, Committee on Appropriations. 02/11/2016This resource provides a recording of and statements from a two-hour, 10-minute Congressional hearing before the Senate Labor, Health and Human Services, and Education Subcommittee on the Zika outbreak and the supplemental funding request to combat the Zika virus. Witnesses from the Centers for Disease Control and Prevention, and National Institute of Allergy and Infectious Diseases discuss work to accelerate optimal vector control strategies, better diagnostics, and vaccine discovery. (Video or Multimedia)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - February 13, 2016 Category: Global & Universal Authors: The U.S. National Library of Medicine Source Type: news
Obama Pitches $1.1 Billion to Fight Opioid, Heroin Addiction
(MedPage Today) -- President's budget includes mandatory funding to get people into treatment
Source: MedPage Today Allergy - February 3, 2016 Category: Allergy & Immunology Source Type: news
U.S. Scientists Are Starting From Ground Zero With The Zika Vaccine
As the research community gears up to address Zika virus, one common question has been why, if we’ve known about Zika since 1947, are we only starting these efforts in 2016? As Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, admitted, the disease is uncharted territory. "We, prior to this time, have really not spent anything on Zika,” he said during a press conference Thursday. Currently, there is no cure and no vaccine for the disease, and diagnosing the disease takes up to two weeks in specialized labs. To ramp up research on the Zika virus threat, the...
Source: Healthy Living - The Huffington Post - January 29, 2016 Category: Consumer Health News Source Type: news
